Abstract
The flaccid pathology associated with intoxication by the botulinum neurotoxins (BoNTs) is the result of the association of the toxin to neuronal-specific host receptors and the cleavage of neuronal substrates, soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins. Each of the seven serotypes of BoNTs (A–G) targets a specific neuronal SNARE protein(s) for cleavage. Neuronal SNARE proteins function in the binding and fusion of neurotransmitter vesicles with a host membrane, and SNARE protein cleavage by the BoNTs disrupts the fusion process leading to host paralysis. The mechanism that BoNTs utilize to bind and cleave the SNARE proteins involves recognizing an extended substrate surface to allow the BoNTs to efficiently cleave the coiled SNARE protein substrate. BoNT serotypes comprise natural variants termed subtypes, which extends the complexity and potential pathology of the BoNTs. Understanding the mechanisms of BoNT action provides tools towards the development of strategies to identify novel small-molecule inhibitors of BoNT catalysis and to extend the use of BoNTs as therapeutic agents.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gill DM (1982) Bacterial toxins: a table of lethal amounts. Microbiol Mol Biol Rev 46(1):86–94
Schulte-Mattler WJ (2008) Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety. CNS Drugs 22(9):725–738
Kessler KR, Benecke R (1997) Botulinum toxin: from poison to remedy. Neurotoxicology 18(3):761–770
Jin Y et al (2009) Disruption of the epithelial barrier by botulinum haemagglutinin (HA) proteins—differences in cell tropism and the mechanism of action between HA proteins of types A or B, and HA proteins of type C. Microbiology 155(Pt 1):35–45
Fujinaga Y et al (2009) A novel function of botulinum toxin-associated proteins: HA proteins disrupt intestinal epithelial barrier to increase toxin absorption. Toxicon 54(5):583–586
Hill KK et al (2007) Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol 189(3):818–832
Arnon SS et al (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285(8):1059–1070
Sonnabend OA et al (1985) Continuous microbiological and pathological study of 70 sudden and unexpected infant deaths: toxigenic intestinal clostridium botulinum infection in 9 cases of sudden infant death syndrome. Lancet 1(8423):237–241
Kozaki S, Notermans S (1980) Stabilities of Clostridium botulinum type B and C toxins in ruminal contents of cattle. Appl Environ Microbiol 40(1):161–162
Jansen BC, Knoetze PC, Visser F (1976) The antibody response of cattle to Clostridium botulinum types C and D toxoids. Onderstepoort J Vet Res 43(4):165–173
Simpson LL (1986) Molecular pharmacology of botulinum toxin and tetanus toxin. Annu Rev Pharmacol Toxicol 26:427–453
Schiavo G et al (1994) Tetanus and botulinum neurotoxins are zinc proteases specific for components of the neuroexocytosis apparatus. Ann N Y Acad Sci 710:65–75
Montecucco C, Schiavo G (1994) Mechanism of action of tetanus and botulinum neurotoxins. Mol Microbiol 13(1):1–8
Foran P, Shone CC, Dolly JO (1994) Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments. Biochemistry 33(51):15365–15374
Jahn R et al (1995) Botulinum and tetanus neurotoxins: emerging tools for the study of membrane fusion. Cold Spring Harb Symp Quant Biol 60:329–335
Ahnert-Hilger G, Bigalke H (1995) Molecular aspects of tetanus and botulinum neurotoxin poisoning. Prog Neurobiol 46(1):83–96
Montecucco C, Schiavo G (1995) Structure and function of tetanus and botulinum neurotoxins. Q Rev Biophys 28(4):423–472
Montecucco C, Schiavo G, Rossetto O (1996) The mechanism of action of tetanus and botulinum neurotoxins. Arch Toxicol Suppl 18:342–354
Pellizzari R et al (1999) Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci 354(1381):259–268
Chen S, Hall C, Barbieri JT (2008) Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin. J Biol Chem 283(30):21153–21159
Schiavo G et al (1992) Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359(6398):832–835
Dekleva ML, Dasgupta BR (1990) Purification and characterization of a protease from Clostridium botulinum type A that nicks single-chain type A botulinum neurotoxin into the di-chain form. J Bacteriol 172(5):2498–2503
Lacy DB et al (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5(10):898–902
Lacy DB et al (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Mol Biol 5(10):898–902
Fischer A et al (2009) Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc Natl Acad Sci U S A 106(5):1330–1335
Breidenbach MA, Brunger AT (2004) Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432(7019):925–929
Henkel JS et al (2009) Catalytic properties of botulinum neurotoxin subtypes A3 and A4. Biochemistry 48(11):2522–2528
Dasgupta BR, Sugiyama H (1972) Isolation and characterization of a protease from Clostridium botulinum type B. Biochim Biophys Acta 268(3):719–729
Hanson MA, Stevens RC (2000) Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 A resolution. Nat Struct Biol 7(8):687–692
Arndt JW et al (2005) Crystal structure of botulinum neurotoxin type G light chain: serotype divergence in substrate recognition. Biochemistry 44(28):9574–9580
Arndt JW et al (2006) Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity. Biochemistry 45(10):3255–3262
Jin R et al (2007) Structural and biochemical studies of botulinum neurotoxin serotype C1 light chain protease: implications for dual substrate specificity. Biochemistry 46(37):10685–10693
Agarwal R et al (2004) Structural analysis of botulinum neurotoxin type E catalytic domain and its mutant Glu212-->Gln reveals the pivotal role of the Glu212 carboxylate in the catalytic pathway. Biochemistry 43(21):6637–6644
Agarwal R, Binz T, Swaminathan S (2005) Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design. Biochemistry 44(35):11758–11765
Rossetto O et al (1994) SNARE motif and neurotoxins. Nature 372(6505):415–416
Sieber JJ et al (2006) The SNARE motif is essential for the formation of syntaxin clusters in the plasma membrane. Biophys J 90(8):2843–2851
McMahon HT, Kozlov MM, Martens S (2010) Membrane curvature in synaptic vesicle fusion and beyond. Cell 140(5):601–605
Smith SM, Renden R, von Gersdorff H (2008) Synaptic vesicle endocytosis: fast and slow modes of membrane retrieval. Trends Neurosci 31(11):559–568
Hangauer DG et al (1985) Modeling the mechanism of peptide cleavage by thermolysin. Ann N Y Acad Sci 439:124–139
Vaidyanathan VV et al (1999) Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage. J Neurochem 72(1):327–337
Binz T et al (2002) Arg(362) and Tyr(365) of the botulinum neurotoxin type a light chain are involved in transition state stabilization. Biochemistry 41(6):1717–1723
Breidenbach MA, Brunger AT (2005) New insights into clostridial neurotoxin-SNARE interactions. Trends Mol Med 11(8):377–381
Chen S, Barbieri JT (2006) Unique substrate recognition by botulinum neurotoxins serotypes A and E. J Biol Chem 281(16):10906–10911
Vaidyanathan VV et al (1999) Proteolysis of SNAP-25 Isoforms by Botulinum Neurotoxin Types A, C, and E. J Neurochem 72(1):327–337
Owen M et al (2010) Ketamine and botulinum: a safe combinationfor the management of childhood strabismus. Strabismus 18(1):8–12
Eubanks LM et al (2010) Identification of a natural product antagonist against the botulinum neurotoxin light chain protease. ACS Med Chem Lett 1(6):268–272
Khan AO (2006) Botulinum toxin A as an intraoperative adjunct to horizontal strabismus surgery. J AAPOS 10(5):494 (author reply pp 494–495)
Lennerstrand G et al (1998) Treatment of strabismus and nystagmus with botulinum toxin type A. An evaluation of effects and complications. Acta Ophthalmol Scand 76(1):27–27
Chen S, Barbieri JT (2009) Engineering botulinum neurotoxin to extend therapeutic intervention. Proc Nat Acad Sci 106(23):9180–9184
Scott AB, Miller JM, Shieh KR (2009) Treating strabismus by injecting the agonist muscle with bupivacaine and the antagonist with botulinum toxin. Trans Am Ophthalmol Soc 107:104–109
Chen S, Kim JJ, Barbieri JT (2007) Mechanism of substrate recognition by botulinum neurotoxin serotype A. J Biol Chem 282(13):9621–9627
Dasgupta BR et al (2005) Botulinum neurotoxin types A, B, and E: fragmentations by autoproteolysis and other mechanisms including by O-phenanthroline-dithiothreitol, and association of the dinucleotides NAD(+)/NADH with the heavy chain of the three neurotoxins. Protein J 24(6):337–368
Bansal S, Khan J, Marsh IB (2008) The role of botulinum toxin in decompensated strabismus. Strabismus 16(3):107–111
Gardner R et al (2008) Long-term management of strabismus with multiple repeated injections of botulinum toxin. J AAPOS 12(6):569–575
Fu Z et al (2006) Light chain of botulinum neurotoxin serotype A: structural resolution of a catalytic intermediate. Biochemistry 45(29):8903–8911
Smith TJ et al (2005) Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun 73(9):5450–5457
Arndt JW et al (2006) A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol 362(4):733–742
Dai Z, Wang YC (1992) Treatment of blepharospasm, hemifacial spasm and strabismus with botulinum A toxin. Chin Med J (Engl) 105(6):476–80
Cordonnier M et al (1994) Treatment of strabismus with botulinum toxin. J Fr Ophtalmol 17(12):755–768
Scott AB (1980) Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus 17(1):21–25
Fernandez-Salas E et al (2004) Is the light chain subcellular localization an important factor in botulinum toxin duration of action? Mov Disord 19(Suppl 8):23–34
Fernandez-Salas E et al (2004) Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proc Natl Acad Sci U S A 101(9):3208–3213
Wang J et al (2011) A Di-leucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: Transfer of longevity to a novel potential therapeutic. J Biol Chem 286(8):6375-6385
Chen S, Barbieri JT (2011) Association of Botulinum neurotoxin serotype A light chain with plasma membrane-bound SNAP-25. J Biol Chem 286(17):15067–15072
Perez-Branguli F, Ruiz-Montasell B, Blasi J (1999) Differential interaction patterns in binding assays between recombinant syntaxin 1 and synaptobrevin isoforms. FEBS Lett 458(1):60–64
Washbourne P et al (2001) Cysteine residues of SNAP-25 are required for SNARE disassembly and exocytosis, but not for membrane targeting. Biochem J 357(Pt 3):625–634
Sutton RB et al (1998) Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution. Nature 395(6700):347–353
Tsai YC et al (2010) Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc Natl Acad Sci U S A 107(38):16554–16559
Thompson AA et al (2011) Structural characterization of three novel hydroxamate-based zinc chelating inhibitors of the clostridium botulinum serotype A neurotoxin light chain metalloprotease reveals a compact binding site resulting from 60/70 loop flexibility. Biochemistry 50(19):4019-4028
Silhar P et al (2010) Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors. J Am Chem Soc 132(9):2868–2869
Roxas-Duncan V et al (2009) Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A. Antimicrob Agents Chemother 53(8):3478–3486
Zuniga JE et al (2010) Iterative structure-based peptide-like inhibitor design against the botulinum neurotoxin serotype A. PLoS One 5(6):e11378
Price J, O’Day J (1993) A comparative study of tear secretion in blepharospasm and hemifacial spasm patients treated with botulinum toxin. J Clin Neuroophthalmol 13(1):67–71
Durham PL, Cady R (2004) Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44(1):35–42 (discussion pp 42–43)
Klein AW (1996) Cosmetic therapy with botulinum toxin, Anecdotal memoirs. Dermatol Surg 22(9):757–759
Chaddock JA et al (2000) A conjugate composed of nerve growth factor coupled to a non-toxic derivative of Clostridium botulinum neurotoxin type A can inhibit neurotransmitter release in vitro. Growth Factors 18(2):147–155
Duggan MJ et al (2002) Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J Biol Chem 277(38):34846–34852
Chen S, Barbieri JT (2007) Multiple pocket recognition of SNAP25 by botulinum neurotoxin serotype E. J Biol Chem 282(35):25540–25547
Ravichandran V, Chawla A, Roche PA (1996) Identification of a novel syntaxin- and synaptobrevin/VAMP-binding protein, SNAP-23, expressed in non-neuronal tissues. J Biol Chem 271(23):13300–13303
Wurzburger MI, Sonksen PH (1996) Natural course of growth hormone hypersecretion in insulin-dependent diabetes mellitus. Med Hypotheses 46(2):145–149
Johansson E et al (1997) Antisecretory factor suppresses intestinal inflammation and hypersecretion. Gut 41(5):642–645
Sorensen JB (2005) SNARE complexes prepare for membrane fusion. Trends Neurosci 28(9):453–455
Duvic M et al (1998) DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. Am J Hematol 58(1):87–90
Kreitman RJ et al (1993) Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia. Leukemia 7(4):553–562
Acknowledgments
JTB acknowledges membership in the GLRCE and support by 1-U54-AI-057153 from Region V Great Lakes Regional Center of Excellence, the National Institute of Allergy and Infectious Diseases (NIAID), and National Institutes of Health Regional Center of Excellence for Bio-defense and Emerging Infectious Diseases Research Program and NIH-AI-030162. Sheng Chen is funded from the Research Grants Council (RGC)/PolyU Competitive Research Grants: G-U662, A-PK05, and G-YJ15.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer New York
About this chapter
Cite this chapter
Chen, S., Barbieri, J. (2014). Protease Activity of the Botulinum Neurotoxins. In: Foster, K. (eds) Molecular Aspects of Botulinum Neurotoxin. Current Topics in Neurotoxicity, vol 4. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9454-6_8
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9454-6_8
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-9453-9
Online ISBN: 978-1-4614-9454-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)